Connect with us
Roche Pharma invested €57 million in Spain in 2025, running 283 clinical trials on 76 molecules with 8,584 patients and 950 researchers across 178 centers. Trials...
At Swiss Biotech Day in Basel, early discussions lacked data, revealing mixed sentiment despite official reports showing strong growth. Switzerland’s biotech sector reached record revenues, stable...
Johnson & Johnson has EU approval for nipocalimab for generalized myasthenia gravis, showing superior control and sustained benefits. Sanofi reported a safer protein COVID-19 vaccine versus...
NurExone Biologic Inc.’s nomination for the 2025 Prix Galien Bridges Award places it alongside Roche and Novo Nordisk, highlighting its rising global visibility. Its exosome-based regenerative...
Roche's CE Mark-approved cobas Mass Spec offers automated, standardized mass spectrometry for over 60 tests, improving care for breast cancer and hormonal therapy patients. It aids...
Roche is acquiring Poseida Therapeutics for up to $1.5 billion, emphasizing its strategic focus on innovative allogeneic CAR-T cancer therapies. Poseida’s candidate P-BCMA-ALLO1 shows promise in...
BaseLaunch, a Basel biotech incubator, gains support from AbbVie, joining Roche, Novo Nordisk, Johnson & Johnson, and CSL Behring. Operated by Basel Area Business & Innovation,...
Roche is set to acquire Carmot Therapeutics, along with three clinical-stage assets for treating obesity and diabetes, for a maximum of €2.85 billion. The agreement involves...
Roche recently partnered with Alnylam for the development and commercialization of a treatment for hypertension in patients with high cardiovascular risk. The Swiss company makes an initial...
In total, the world's five hundred largest family companies together generate $8.02 trillion and employ 24.5 million people worldwide. These 500 companies are growing twice as...